The concept is furthered by the observation that the ablation of CCR2 in HexB−/− mouse model of Sandhoff disease results in reduced PBMCs infiltration in the brain parenchyma and ameliorates the clinical progression of the disease by reducing neuroinflammation, and hence links reduction in CCR2+ PBMCs with neuroprotection [23]. The gene discussed is HEXB; the disease is Sandhoff disease.